Portfolio Press Release
January 13, 2021
Landos Biopharma guns for a $100M IPO to boost AI autoimmune R&D work
Read more
December 08, 2020
Pipeline Therapeutics to Participate in the 2020 RBC Capital Markets and SVB Leerink Private Company Conferences
Read more
Oct. 14, 2020
Totient Leverages Integral Molecular's Membrane Proteome Array to Advance Cancer Therapeutic Discovery
Read more
Sept. 18, 2020
Pipeline Therapeutics Appoints Lori Lyons-Williams to its Board of Directors
Read more
Sept. 10, 2020
Totient Partners with Ginkgo Bioworks to Apply Unique Discovery Platform to COVID-19 Antibody Efforts
Read more
Sept. 10, 2020
Totient Comes Out of Stealth with Novel COVID-19 Program and $10M in Seed Funding for AI-Driven Drug Discovery Platform
Read more
July 28, 2020
Pipeline Therapeutics to Present at 3 Upcoming Investor Conferences
Read more
July 23, 2020
Pipeline Therapeutics Initiates Phase 1/2a Clinical Trial of PIPE-505 in Sensorineural Hearing Loss
Read more
July 17, 2020
X-Vax Technology Appoints Issac Blech as Vice Chairman to its Board of Directors
Read more
July 14, 2020
Landos Biopharma Announces First Human Dosing in a Phase 1 Study of NX-13, its novel candidate for Inflammatory Bowel Disease
Read more
Dec 2019
Pipeline Therapeutics Completes $30 Million Series B Financing
Read more
Nov 2019
Landos to Present at the 31st Annual Piper Jaffray Healthcare Conference
Read more
Sept 2019
Tangible Science, VSP Optics introduce Unity BioSync Contact Lenses
Read more
Aug 2019
Landos launches two phase II trials
Read more
Aug 2019
Landos Biopharma Completes $60 Million Series B
Read more
Jul 2019
X-Vax Technology Raises $56 Million in Upsized Series A
Read more
May 2019
Landos Biopharma Announces Publication of Results from First-in-Human Phase 1 Study of BT-11 in Healthy Volunteers
Read more
